Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
AARD Stock Chart & Stats
$4.30
--
Market closed
$4.30
--
Day’s Range― - ―
52-Week Range$3.35 - $17.94
Previous CloseN/A
VolumeN/A
Average Volume (3M)166.37K
Market Cap
$93.81M
Enterprise Value$47.20M
Total Cash (Recent Filing)$110.03M
Total Debt (Recent Filing)$441.00K
Price to Earnings (P/E)―
Beta2.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding21,816,042
10 Day Avg. Volume148,283
30 Day Avg. Volume166,372
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)2.42
Price to Sales (P/S)0.00
P/FCF Ratio-4.75
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.36K
Enterprise Value/Ebitda-0.77
Forecast
1Y Price Target
$13.26Price Target Upside208.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayA cash balance projected to support ongoing operations for an extended period reduces near-term financing pressure and allows time to address safety issues without immediate dilution.
Dose OptimizationModeling indicates that substantially lower therapeutic doses may avoid the reversible cardiac electrical change while preserving clinical benefit, creating a feasible path for continued development if accepted by regulators.
Early Unblinding PotentialPausing the late-stage trial could permit early unblinding and detection of efficacy signals from already enrolled patients, which may provide investors with informative data to reassess the program.
Bears Say
Analyst Sentiment And Market ImpactAnalyst downgrades and suspended price targets following the safety observations could weigh on market sentiment and limit near-term upside until regulatory clarity is achieved.
Program Disruption And DelaysThe voluntary pause of the pivotal study removes a major development catalyst, delays pivotal results, and increases uncertainty around timelines for bringing the drug to market.
Regulatory SensitivityRegulatory authorities' caution around heart-related findings for chronic weight therapies raises the likelihood of stringent review, additional safety requirements, or delays to restarting trials.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $3.35 and its highest was $17.94 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $93.81M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Undervalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,816,042 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aardvark Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.26 (208.37% Upside)
$13.26 (208.37% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-48.06%
Trailing 12-Months
Asset Growth
59.10%
Trailing 12-Months
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
AARD Stock 12 Month Forecast
Average Price Target
$13.26
▲(208.37% Upside)
Technical Analysis
Ownership Overview
15.01% Insiders
3.95% Mutual Funds
28.05% Other Institutional Investors
47.36% Public Companies and Individual Investors